The PARP inhibitor veliparib has been combined with radiotherapy for breast cancer patients with inflammatory disease or locoregionally recurrent disease (NCT01477489) and is currently being examined in breast cancer patients in combination with preoperative radiotherapy (NCT01618357). This evidence concerns the gene PARP1 and breast carcinoma.